09:59 AM EST - Merus Labs International Inc. : announced today that it has signed a letter of intent to acquire the rights to manufacture, market, and sell a branded prescription medicine product mainly for the European market and Canada. The product is being divested by a large multinational pharmaceutical company. In the calendar year 2011, the product had net sales of approximately $23 million U.S. in the applicable territories. Merus Labs International Inc.
shares T.MSL are trading unchanged at $1.65.
